The data showed that patients who switched after failing treatment on an interferon beta -- such as Biogen Idec's
Teva is pushing its data hard, because relative newcomer Tysabri -- from Biogen and Elan
Last year Copaxone's global sales increased 21% year over year, so it looks like Teva is doing a pretty good job selling the drug. Hopefully, as Biogen and Elan continue to push toward their own goal of 100,000 patients using Tysabri by the end of 2010, Teva will continue to push back. Yesterday's data won't hurt.
Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Biogen is a pick of the Stock Advisor newsletter. Pfizer is a pick of both the Income Investor and Inside Value newsletters. The Fool has a disclosure policy.